Were Serge Saxonov’s TXG share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were executed under Serge Saxonov’s Rule 10b5-1 trading plan adopted on November 29, 2025. Such plans pre-schedule trades, indicating the timing of these sales was set in advance.

What prices did Serge Saxonov receive for his TXG share sales?

On May 26, 2026, he sold shares at a weighted average price of $24.7092. On May 22, 2026, the weighted average sale price was $24.4415. Footnotes note each transaction was executed in multiple trades within narrow price ranges.

10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open‑market sales of Class A Common Stock primarily tied to tax withholding on equity awards. On May 26, 2026, he sold 10,718 shares at a weighted average price of $24.7092 per share. On May 22, 2026, he sold 18,175 shares at a weighted average price of $24.4415 per share. A footnote states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units and that the transactions were effected under his Rule 10b5‑1 trading plan adopted on November 29, 2025. After these transactions, Saxonov directly holds 1,138,380 shares, with additional indirect holdings through the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, for which he serves as trustee.

Insider Trade Summary 10b5-1

Net Seller: 28,893 shares ($709,057)

Net Sell 5 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 28,893 shs ($709K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	10,718	$24.7092	$265K
Sale	Class A Common Stock	18,175	$24.4415	$444K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,138,380 shares (Direct, null); Class A Common Stock — 27 shares (Indirect, See footnote)

Footnotes (1)

The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares sold May 26, 2026: 10,718 shares at $24.7092 Shares sold May 22, 2026: 18,175 shares at $24.4415 Total shares sold: 28,893 shares +5 more

8 metrics

Shares sold May 26, 2026 10,718 shares at $24.7092 Open-market sale of Class A Common Stock

Shares sold May 22, 2026 18,175 shares at $24.4415 Open-market sale of Class A Common Stock

Total shares sold 28,893 shares Net shares sold across two open-market transactions

Direct holdings after May 26 sale 1,138,380 shares Class A Common Stock held directly by Serge Saxonov

Andromeda Trust holdings 71,644 shares Indirect Class A holdings; Saxonov serves as trustee

Y/S Descendants' Trust holdings 213,250 shares Indirect Class A holdings; Saxonov serves as trustee

Y/S Pot Trust holdings 27 shares Indirect Class A holdings; Saxonov serves as trustee

Net buy/sell direction Net sale of 28,893 shares NetBuySellShares from transaction summary

Key Terms

Rule 10b5-1 trading plan, restricted stock units, tax withholding obligations, weighted average sale price, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."

weighted average sale price financial

"This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price."

trustee financial

"The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 05:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last)

(First)

(Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	05/22/2026		S⁽¹⁾		18,175	D	$24.4415	1,149,098	D
Class A Common Stock	05/26/2026		S⁽²⁾		10,718	D	$24.7092⁽³⁾	1,138,380	D
Class A Common Stock								27	I	See footnote⁽⁴⁾
Class A Common Stock								213,250	I	See footnote⁽⁵⁾
Class A Common Stock								71,644	I	See footnote⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

3. This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

6. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TXG CEO Serge Saxonov report on this Form 4?

Serge Saxonov reported selling 10,718 shares on May 26, 2026 and 18,175 shares on May 22, 2026. Both were open-market sales of 10x Genomics Class A Common Stock at weighted average prices around $24.50 per share.

Why did TXG CEO Serge Saxonov sell shares according to this filing?

The filing states the shares were sold to cover tax withholding obligations related to vesting restricted stock units. This means the sales were made to satisfy tax liabilities arising from equity compensation rather than discretionary portfolio changes.

How many 10x Genomics shares does Serge Saxonov hold after these sales?

After the reported transactions, Serge Saxonov directly holds 1,138,380 shares of 10x Genomics Class A Common Stock. He also has indirect holdings through several trusts, where he serves as trustee, with separate reported share balances.

What indirect TXG holdings for Serge Saxonov are disclosed in this Form 4?

The filing lists indirect holdings of 71,644 shares, 213,250 shares, and 27 shares of Class A Common Stock. These are held by the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, respectively, with Serge Saxonov serving as trustee.